BRPI1010718A2 - sistemas modelo e regimes de tratamento para tratar doença neurológica. - Google Patents

sistemas modelo e regimes de tratamento para tratar doença neurológica.

Info

Publication number
BRPI1010718A2
BRPI1010718A2 BRPI1010718A BRPI1010718A BRPI1010718A2 BR PI1010718 A2 BRPI1010718 A2 BR PI1010718A2 BR PI1010718 A BRPI1010718 A BR PI1010718A BR PI1010718 A BRPI1010718 A BR PI1010718A BR PI1010718 A2 BRPI1010718 A2 BR PI1010718A2
Authority
BR
Brazil
Prior art keywords
treatment regimens
neurological disease
model systems
treat neurological
treat
Prior art date
Application number
BRPI1010718A
Other languages
English (en)
Inventor
Jonathan David Garman
Michael Tymianski
Original Assignee
Nono Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nono Inc filed Critical Nono Inc
Publication of BRPI1010718A2 publication Critical patent/BRPI1010718A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI1010718A 2009-06-10 2010-06-10 sistemas modelo e regimes de tratamento para tratar doença neurológica. BRPI1010718A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18598909P 2009-06-10 2009-06-10
PCT/US2010/038200 WO2010144721A2 (en) 2009-06-10 2010-06-10 Model systems and treatment regimes for treatment of neurological disease

Publications (1)

Publication Number Publication Date
BRPI1010718A2 true BRPI1010718A2 (pt) 2016-03-15

Family

ID=43309469

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010718A BRPI1010718A2 (pt) 2009-06-10 2010-06-10 sistemas modelo e regimes de tratamento para tratar doença neurológica.

Country Status (14)

Country Link
US (2) US8940699B2 (pt)
EP (2) EP3808366A1 (pt)
JP (2) JP6005514B2 (pt)
CN (1) CN102458441A (pt)
AU (1) AU2010258664B2 (pt)
BR (1) BRPI1010718A2 (pt)
CA (1) CA2765169C (pt)
DK (1) DK2440230T3 (pt)
ES (1) ES2847293T3 (pt)
HR (1) HRP20210112T1 (pt)
HU (1) HUE053131T2 (pt)
PL (1) PL2440230T3 (pt)
PT (1) PT2440230T (pt)
WO (1) WO2010144721A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
BRPI1010718A2 (pt) 2009-06-10 2016-03-15 Nono Inc sistemas modelo e regimes de tratamento para tratar doença neurológica.
ES2655112T3 (es) 2010-08-12 2018-02-16 Nono Inc. Tratamiento de una lesión penetrante en el cerebro
CA2839630A1 (en) 2011-06-24 2012-12-27 Nono Inc. Combination therapy for ischemia
KR20200057802A (ko) * 2011-12-13 2020-05-26 노노 인코포레이티드 지주막하 출혈 및 허혈에 대한 치료법
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
AU2013204309A1 (en) * 2012-11-13 2014-05-29 Biodiem Limited Therapeutic Compounds and Uses Thereof
PL2925338T3 (pl) * 2012-11-28 2019-11-29 Nono Inc Liofilizowana formulacja TAT-NR2B9C
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
DK3149048T3 (en) * 2014-05-28 2020-04-14 Nono Inc Chloridsalt af tat-nr2b9c
KR20180135493A (ko) * 2016-04-27 2018-12-20 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경독성 관련 손상의 치료 방법
ES2869300T3 (es) 2016-04-27 2021-10-25 Biocells Beijing Biotech Co Ltd Péptido terapéutico para las lesiones relacionadas con la neurotoxicidad excitadora
CN110049994B (zh) * 2016-12-08 2023-05-02 拜西欧斯(北京)生物技术有限公司 一种缀合物及其应用
US11767344B2 (en) 2017-07-05 2023-09-26 Biocells (Beijing) Biotech Co., Ltd. Pharmaceutically acceptable salts of polypeptides and methods of inhibiting the interaction between psd-95 and n-methyl-d-aspartic acid receptor (nmdar)
WO2019006692A1 (zh) * 2017-07-05 2019-01-10 拜西欧斯(北京)生物技术有限公司 用于治疗、改善或预防神经***相关病症的化合物及其用途
EP3693001A4 (en) * 2017-09-30 2021-07-07 Biocells (Beijing) Biotech Co., Ltd. PEPTIDIC COMPOSITION ALLOWING THE TREATMENT OF INJURIES RELATED TO EXCITING NEUROTOXICITY
CN113150065B (zh) 2021-03-11 2022-07-08 武汉英纳氏药业有限公司 一种合成肽及其应用
CN113121641B (zh) 2021-03-11 2022-11-01 武汉英纳氏药业有限公司 一类多功能多肽及其在医药领域的应用
CN113735938A (zh) 2021-07-30 2021-12-03 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用
CN114469084B (zh) * 2022-04-02 2022-06-24 剑博微电子(深圳)有限公司 一种基于高精度adc的血氧监测***

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148711A1 (en) 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
GB0025473D0 (en) 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
WO2004045535A2 (en) * 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
WO2004071531A1 (en) 2003-02-13 2004-08-26 Licentia Oy Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
JP2006525270A (ja) 2003-05-02 2006-11-09 パイオン ドイチュラント ゲーエムベーハー 脳梗塞の処置のための非神経毒性プラスミノーゲン活性剤の静脈内注射
JP5746468B2 (ja) * 2006-07-11 2015-07-08 ノノ インコーポレイテッド 発熱を伴う脳卒中を処置する方法および組成物
EP1884521A1 (en) * 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
ES2446292T3 (es) * 2007-03-02 2014-03-07 Nono Inc. Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N
WO2009006611A1 (en) 2007-07-03 2009-01-08 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
DK2320927T3 (en) 2008-07-09 2015-09-14 Univ Copenhagen Modified peptides as potent inhibitors of the PSD-95 / NMDA receptor interaction
BRPI1010718A2 (pt) 2009-06-10 2016-03-15 Nono Inc sistemas modelo e regimes de tratamento para tratar doença neurológica.
CA2839630A1 (en) 2011-06-24 2012-12-27 Nono Inc. Combination therapy for ischemia
KR20200057802A (ko) 2011-12-13 2020-05-26 노노 인코포레이티드 지주막하 출혈 및 허혈에 대한 치료법
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia

Also Published As

Publication number Publication date
JP6220371B2 (ja) 2017-10-25
PL2440230T3 (pl) 2021-06-14
US9610323B2 (en) 2017-04-04
CN102458441A (zh) 2012-05-16
HUE053131T2 (hu) 2021-06-28
AU2010258664B2 (en) 2015-05-28
ES2847293T3 (es) 2021-08-02
DK2440230T3 (da) 2021-01-18
WO2010144721A2 (en) 2010-12-16
PT2440230T (pt) 2021-02-03
EP2440230A2 (en) 2012-04-18
CA2765169C (en) 2019-06-18
EP3808366A1 (en) 2021-04-21
US20120269733A1 (en) 2012-10-25
AU2010258664A1 (en) 2012-01-12
CA2765169A1 (en) 2010-12-16
EP2440230B1 (en) 2020-11-11
JP2016041731A (ja) 2016-03-31
US20150202253A1 (en) 2015-07-23
US8940699B2 (en) 2015-01-27
JP6005514B2 (ja) 2016-10-12
EP2440230A4 (en) 2014-05-28
JP2012530057A (ja) 2012-11-29
WO2010144721A3 (en) 2011-04-21
HRP20210112T1 (hr) 2021-04-16

Similar Documents

Publication Publication Date Title
BRPI1010718A2 (pt) sistemas modelo e regimes de tratamento para tratar doença neurológica.
CA145381S (en) Pet treat
CA145379S (en) Pet treat
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
BRPI0915112A2 (pt) cateter de entalhe para tratar válvulas cardíacas doentes
BR112012008367A2 (pt) sistemas e métodos de tratamento de águas residuais.
BR112013018469A2 (pt) dispositivos e métodos para tratamento de tecidos
BRPI1015233A2 (pt) métodos para tratar ou prevenir a fadiga
IT1400425B1 (it) Modified snrnas for use in therapy.
BR112012000254A2 (pt) análogos de tofa úteis no tratamento de distúrbios ou condições dermatológicas.
BRPI0907135A2 (pt) Processos de tratamento de dor crônica
BR112014006419A2 (pt) métodos para tratar um paciente com câncer, kit e artigo
BRPI1013361A2 (pt) método para evitar e tratar hipermeabilidade.
BRPI0919127A2 (pt) métodos para tratamento de água
BRPI1008517A2 (pt) direcionamento duplo de mir-208 e mir-499 no tratamento de doenças cardíacas.
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BR112014009789A2 (pt) cisteamina no tratamento da doença fibrótica
LTPA2020511I1 (lt) Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui
BRPI1010086A2 (pt) método e produtos para tratamento de doenças
CA145380S (en) Pet treat
BRPI0906606A2 (pt) Tratamento terapêutico para condições do pulmão.
IL214133A0 (en) Skin treatment
BR112013004683A2 (pt) "conjunto de cateter para tratamento de nervo"
BRPI1013903A2 (pt) tratamentos terapêuticos utilizando centaquina
BR112012013591A2 (pt) dispositivo para tratamento eletroterapêutico

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal: appeal against refusal